Early diagnosis saves lives

We are helping conquer cancer and fibrotic diseases by extracting invaluable clinical insights from patients’ medical images.

We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs. We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients.

About Us

We provide invaluable clinical insights where others see only images

We are a game changer in the medical space. Deploying our clinical expertise, proprietary technologies, and data science experience, we generate unprecedented insights from medical images for both drug development and patient care. We bring answers to your concerns and help therapeutic decisions.

Contact us

Going beyond images

Our imaging solutions make an impact throughout the entire patient journey, from drug development to patient care.

Imaging Services for Oncology Clinical Trials

With iCRO we offer best-in-class end-to-end image management in oncology trials. We provide our global biopharma customers with key data on patients’ response to candidate drugs from phase I through phase III studies. Imaging Lab, our enriched iCRO offering, drives drug development success with transformative AI-powered insights.

Learn More

End-to-end CADe/CADx software as medical devices

With iBiopsy® we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. iBiopsy® is currently under development.

Learn More

The latest from Median

Median Technologies has officially commenced operations with all investigator sites participating in the pivotal validation plan for its iBiopsy® Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx Software as Medical Device (SaMD).
Read more
Median reports today its business indicators for the first half of 2023 for the iCRO activity and the iBiopsy® activity. The Company also announces the first step of ths refinancing plan.
Read more
The study showed that CT-based radiomics can accurately predict the histopathological subtype of NSCLC patients, offering a less invasive and more cost-effective alternative to traditional tissue analysis methods.
Read more
AI-powered medical image analysis has the potential to serve as predictive biomarkers for guiding targeted therapies in the future
Read more
Median will be exhibiting at the ESMO Congress on October 20 – 24 in Madrid. Happy to see you there at IFEMA Madrid, Hall 5, booth #522!
Read more

Invest in us

Our innovative technology and leading expertise is opening up new possibilities for biopharmaceutical companies and healthcare professionals around the world.

By successfully helping improve the lives of millions, we are delivering value for our investors and partners.

Our company is listed on Euronext Growth and our shareholding structure reflects our global reach, with major shareholders from Europe, USA, and Asia.

Investors

Work with us

Being part of Median doesn’t just mean working for a company at the cutting edge of medical imaging. You become part of a team striving to improve outcomes for people suffering from life-threatening diseases. Join us!

Careers